ESO-101 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 98 | 好酸球性消化管疾患 | 3 |
98. 好酸球性消化管疾患
臨床試験数 : 171 / 薬物数 : 184 - (DrugBank : 47) / 標的遺伝子数 : 42 - 標的パスウェイ数 : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04849390 (ClinicalTrials.gov) | June 29, 2021 | 2/4/2021 | A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis | A Randomized, Placebo-controlled, Double-blind Trial Evaluating the Efficacy, Tolerability and Safety of ESO-101 in Adult Patients With Active Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: ESO-101;Drug: Placebo | EsoCap AG | FGK Clinical Research GmbH;FGK Representative Service B.V. | Recruiting | 18 Years | 70 Years | All | 42 | Phase 2 | Germany;Netherlands;Spain;Switzerland |
| 2 | EUCTR2020-000082-16-DE (EUCTR) | 21/01/2021 | 29/07/2020 | A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagus | A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis | Active eosinophilic esophagitis MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eosinophilic oesophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: ESO-101 Product Code: ESO-101 INN or Proposed INN: mometasone Other descriptive name: MOMETASONE FUROATE | EsoCap AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 42 | Phase 2 | Spain;Netherlands;Germany;Switzerland | ||
| 3 | EUCTR2020-000082-16-NL (EUCTR) | 29/10/2020 | 03/09/2020 | A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagus | A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis | Active eosinophilic esophagitis MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eosinophilic oesophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: ESO-101 Product Code: ESO-101 INN or Proposed INN: mometasone Other descriptive name: MOMETASONE FUROATE | EsoCap AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 42 | Phase 2 | Spain;Germany;Netherlands;Switzerland |